Résultats de la recherche

search

Rechercher les filtres

Organisation
BioSyent Inc.
BioSyent logo.png
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
06 mars 2025 17h45 HE | BioSyent Inc.
MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent logo.png
BioSyent Declares First Quarter 2025 Dividend
30 janv. 2025 17h00 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Jan. 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent Announces Renewal of Normal Course Issuer Bid
16 déc. 2024 08h30 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted...
BioSyent logo.png
BioSyent Releases Financial Results for Q3 and YTD 2024
20 nov. 2024 08h00 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended...
BioSyent logo.png
BioSyent Declares Fourth Quarter 2024 Dividend
20 nov. 2024 07h55 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
13 nov. 2024 16h30 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent logo.png
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
20 sept. 2024 09h00 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has...
BioSyent logo.png
BioSyent Releases Financial Results for Q2 and H1 2024
26 août 2024 16h45 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30,...
BioSyent logo.png
BioSyent Declares Third Quarter 2024 Dividend
26 août 2024 16h30 HE | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent In-Licenses Endocrinology Product for Canada
12 juin 2024 09h00 HE | BioSyent Inc.
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....